<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001880</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2021-08573</org_study_id>
    <secondary_id>NCI-2021-08573</secondary_id>
    <secondary_id>A092001</secondary_id>
    <secondary_id>A092001</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <nct_id>NCT05001880</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma</brief_title>
  <official_title>Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial compares the usual treatment alone to using immunotherapy (atezolizumab)&#xD;
      plus the usual treatment in treating patients with peritoneal mesothelioma. The usual&#xD;
      treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and&#xD;
      pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a&#xD;
      monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.&#xD;
      Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune&#xD;
      system attack the cancer, and may interfere with the ability of tumor cells to grow and&#xD;
      spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and&#xD;
      atezolizumab results in a superior best response rate than carboplatin, pemetrexed and&#xD;
      bevacizumab in patients with peritoneal mesothelioma as determined by (RECIST).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety, major pathologic response rates, and completeness of&#xD;
      cytoreduction of patients treated with neoadjuvant carboplatin, pemetrexed, bevacizumab and&#xD;
      atezolizumab or carboplatin, pemetrexed and bevacizumab.&#xD;
&#xD;
      II. To determine the safety of patients treated with palliative carboplatin, pemetrexed,&#xD;
      bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.&#xD;
&#xD;
      III. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and&#xD;
      atezolizumab results in a superior metabolic response rate than carboplatin, pemetrexed and&#xD;
      bevacizumab as determined by Positron Emission Tomography (PET) Response Criteria in Solid&#xD;
      Tumors.&#xD;
&#xD;
      IV. Explore the value that analysis of secondary computed tomography (CT) findings and&#xD;
      quantitative fludeoxyglucose F-1 (FDG)-PET imaging adds to prognostic information and&#xD;
      response assessment in this disease.&#xD;
&#xD;
      V. Determine the number of patients who were deemed to have unresectable disease who are able&#xD;
      to undergo surgery following treatment with carboplatin, pemetrexed, bevacizumab and&#xD;
      atezolizumab or carboplatin, pemetrexed and bevacizumab due to dramatic response.&#xD;
&#xD;
      VI. To compare the progression-free survival and overall survival between arms. VII. Results&#xD;
      of the primary analysis will be examined for consistency, while taking into account the&#xD;
      stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether blood-based biomarkers including our recently described cell-free&#xD;
      chromosomal junctions, soluble mesothelin-related peptides and megakaryocyte potentiating&#xD;
      factor correlate with clinical outcomes data (i.e. overall survival [OS], progression-free&#xD;
      survival [PFS], recurrence, response, etc.).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive atezolizumab intravenously (IV) over 60 minutes, bevacizumab IV over&#xD;
      30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1.&#xD;
      Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and&#xD;
      hyperthermic intraperitoneal chemotherapy (HIPEC). Patients not eligible for surgery may&#xD;
      receive atezolizumab and bevacizumab in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM II: Patients receive bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes,&#xD;
      and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4&#xD;
      cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks,&#xD;
      patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may&#xD;
      receive bevacizumab with or without atezolizumab at the discretion of the investigator in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for up to 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">August 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 4 years after study activation</time_frame>
    <description>Will be compared between arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major pathologic response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square test will be used to compare the rates between arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completeness of cytoreduction</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate to surgical resection among those not deemed to be surgical candidates</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will estimate the conversion rate to surgical resection among those not deemed to be surgical candidates prior to treatment and provide the 95% confidence interval as well.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, assessed up to 3 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From study entry to death from any cause, assessed up to 3 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Soluble mesothelin-related peptides and megakaryocyte potentiating factor</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be correlated with clinical endpoints including confirmed response, overall survival, PFS, recurrence, and adverse events. Statistical and graphical techniques will be used to explore the relationships between the translational and clinical data. For time-to-event endpoints, will use Cox proportional hazards models, and for confirmed response will use Logistic regression models. In addition, will use the Chi-square or Fisher's exact tests to test the association between categorical marker data and confirmed response/adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Peritoneal Malignant Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive atezolizumab IV over 60 minutes, bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive atezolizumab and bevacizumab in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive bevacizumab with or without atezolizumab at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <other_name>MPDL 3280A</other_name>
    <other_name>MPDL 328OA</other_name>
    <other_name>MPDL-3280A</other_name>
    <other_name>MPDL3280A</other_name>
    <other_name>MPDL328OA</other_name>
    <other_name>RG7446</other_name>
    <other_name>RO5541267</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>ABP 215</other_name>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar ABP 215</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar GB-222</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar Mvasi</other_name>
    <other_name>Bevacizumab Biosimilar MYL-1402O</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>Bevacizumab Biosimilar Zirabev</other_name>
    <other_name>Bevacizumab-awwb</other_name>
    <other_name>Bevacizumab-bvzr</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Mvasi</other_name>
    <other_name>MYL-1402O</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
    <other_name>Zirabev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>Cytoreduction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>Undergo HIPEC</description>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>Pemfexy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant peritoneal mesothelioma for which&#xD;
             there has been no prior treatment. Given the indolent nature of well-differentiated&#xD;
             papillary mesothelioma and multicystic mesothelioma, patients with these variants are&#xD;
             not eligible for participation&#xD;
&#xD;
               -  All slides including performed immunostains from diagnostic tumor tissue together&#xD;
                  with pathology report for retrospective central pathology review&#xD;
&#xD;
          -  Must have measurable disease per RECIST version (v) 1.1&#xD;
&#xD;
          -  Not pregnant and not nursing, because this study involves an agent that has known&#xD;
             genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing&#xD;
             potential only, a negative pregnancy test done =&lt; 28 days prior to registration is&#xD;
             required&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Leukocytes &gt;= 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Creatinine clearance &gt;= 45 mL/min/1.73 m^2 for patients with creatinine levels above&#xD;
             institutional normal&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =&lt; 3.0 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Urine protein:creatinine (UPC) ratio &lt; 1, or urine protein: =&lt; 1+&#xD;
&#xD;
          -  No prior systemic therapy for peritoneal mesothelioma is allowed. No concurrent&#xD;
             radiotherapy is allowed&#xD;
&#xD;
          -  No active or history of autoimmune disease or immune deficiency, including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome,&#xD;
             or multiple sclerosis, with the following exceptions:&#xD;
&#xD;
               -  Patients with a history of autoimmune-related hypothyroidism who are on&#xD;
                  thyroid-replacement hormone are eligible for the study&#xD;
&#xD;
               -  Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen&#xD;
                  are eligible for the study&#xD;
&#xD;
          -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
             dermatologic manifestations only (e.g., patients with psoriatic arthritis are&#xD;
             excluded) are eligible for the study provided all of following conditions are met:&#xD;
&#xD;
               -  Rash must cover &lt; 10% of body surface area&#xD;
&#xD;
               -  Disease is well controlled at baseline and requires only low-potency topical&#xD;
                  corticosteroids&#xD;
&#xD;
               -  No occurrence of acute exacerbations of the underlying condition requiring&#xD;
                  psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents,&#xD;
                  oral calcineurin inhibitors, or high-potency or oral corticosteroids within the&#xD;
                  previous 12 months&#xD;
&#xD;
          -  No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan&#xD;
&#xD;
          -  No prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Central nervous system (CNS) metastases must have been treated with local therapy&#xD;
             (surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose&#xD;
             (10 mg or prednisone equivalent or less)&#xD;
&#xD;
          -  Patients who have received live attenuated vaccines within 30 days of the first dose&#xD;
             of trial treatment are eligible at the discretion of the investigator. All seasonal&#xD;
             influenza vaccines and vaccines intended to prevent SARS-CoV-2 and coronavirus disease&#xD;
             2019 (COVID-19) are allowed&#xD;
&#xD;
          -  No history of inadequately controlled hypertension (defined as systolic blood pressure&#xD;
             &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg)&#xD;
&#xD;
          -  No history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, such as cerebrovascular accidents&#xD;
             within 6 months prior to randomization, myocardial infarction within 6 months prior to&#xD;
             randomization, unstable angina, New York Heart Association (NYHA) grade II or greater&#xD;
             congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by&#xD;
             medication or potentially interfering with study treatment&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, such as cerebrovascular accidents&#xD;
             within 12 months prior to randomization, myocardial infarction within 12 months prior&#xD;
             to randomization, unstable angina, New York Heart Association (NYHA) grade II or&#xD;
             greater CHF, or serious cardiac arrhythmia uncontrolled by medication or potentially&#xD;
             interfering with study treatment&#xD;
&#xD;
          -  No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or&#xD;
             recent arterial thrombosis) within 6 months prior to randomization&#xD;
&#xD;
          -  No history of grade &gt;= 4 venous thromboembolism&#xD;
&#xD;
          -  No history or evidence upon physical or neurological examination of central nervous&#xD;
             system&#xD;
&#xD;
          -  No history of grade &gt;= 2 hemoptysis (defined as &gt;= 2.5 mL of bright red blood per&#xD;
             episode) within 1 month prior to screening&#xD;
&#xD;
          -  No history or evidence of inherited bleeding diathesis or significant coagulopathy at&#xD;
             risk of bleeding (i.e., in the absence of therapeutic anticoagulation)&#xD;
&#xD;
          -  No major surgical procedure or significant traumatic injury within 28 days prior to&#xD;
             initiation of study treatment (diagnostic laparoscopy is allowed as part of diagnosing&#xD;
             peritoneal mesothelioma)&#xD;
&#xD;
          -  No core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to initiation of study treatment&#xD;
&#xD;
          -  Placement of a vascular access device should be at least 2 days prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          -  No active infection requiring IV antibiotics at the time of initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  No history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal&#xD;
             abscess, or active GI bleeding within 6 months prior to randomization&#xD;
&#xD;
          -  No serious, non-healing wound, active ulcer, or untreated bone fracture&#xD;
&#xD;
          -  No other malignancy within 5 years prior to randomization, except for localized cancer&#xD;
             in situ, such as basal or squamous cell skin cancer&#xD;
&#xD;
          -  Patients with a creatinine clearance between 45 and 79 mL/min should not use ibuprofen&#xD;
             or other nonsteroidal anti-inflammatory drug (NSAIDs) for 2 days before, the day of,&#xD;
             and 2 days following pemetrexed administration&#xD;
&#xD;
          -  No treatment with immunosuppressive medication (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or&#xD;
             anticipation of need for systemic immunosuppressive medication during study treatment,&#xD;
             with the following exceptions:&#xD;
&#xD;
               -  Patients who received acute, low-dose systemic immunosuppressant medication or a&#xD;
                  one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of&#xD;
                  corticosteroids for a contrast allergy) may be eligible for the study&#xD;
&#xD;
               -  Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids&#xD;
                  for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose&#xD;
                  corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible&#xD;
                  for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron S Mansfield</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliance for Clinical Trials in Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance for Clinical Trials in Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron S. Mansfield</last_name>
      <phone>507-293-0569</phone>
      <email>mansfield.aaron@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron S. Mansfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Aaron S. Mansfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

